Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome

Junichi Kaburaki, Masataka Kuwana, Mihoko Yamamoto, Shinichi Kawai, Eiji Matsuura, Yasuo Ikeda

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A portion of anticardiolipin antibodies is defined as phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and recognizes the conformationally altered β2-GPI which interacts with anionic phospholipids. We studied the clinical significance of IgG phospholipid-dependent anti-β2-GPI antibodies in patients with antiphospholipid syndrome (APS). The subjects consisted of 60 APS patients. IgG phospholipid-dependent anti-β2-GPI antibodies were detected by ELISA in 32 of the 60 patients (53%). Significantly higher incidences of prolonged APTT and lupus anticoagulants were found in patients with these anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash, serositis, LE cell preparation and anti-Sm antibodies were found in patients with these anti-β2-GPI antibodies. It was found that 88% of the patients with these anti-β2-GPI antibodies satisfied less than five of the revised criteria items for the classification of SLE. These findings indicate the clinical characteristics of APS patients with IgG phospholipid-dependent anti-β2-GPI antibodies.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalInternal Medicine
Volume35
Issue number2
Publication statusPublished - Feb 1996
Externally publishedYes

Fingerprint

Antiphospholipid Syndrome
Phospholipids
Glycoproteins
Antibodies
Immunoglobulin G
Serositis
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Incidence
Exanthema
Anti-Idiotypic Antibodies
Neutrophils
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Kaburaki, J., Kuwana, M., Yamamoto, M., Kawai, S., Matsuura, E., & Ikeda, Y. (1996). Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome. Internal Medicine, 35(2), 105-110.

Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome. / Kaburaki, Junichi; Kuwana, Masataka; Yamamoto, Mihoko; Kawai, Shinichi; Matsuura, Eiji; Ikeda, Yasuo.

In: Internal Medicine, Vol. 35, No. 2, 02.1996, p. 105-110.

Research output: Contribution to journalArticle

Kaburaki, J, Kuwana, M, Yamamoto, M, Kawai, S, Matsuura, E & Ikeda, Y 1996, 'Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome', Internal Medicine, vol. 35, no. 2, pp. 105-110.
Kaburaki, Junichi ; Kuwana, Masataka ; Yamamoto, Mihoko ; Kawai, Shinichi ; Matsuura, Eiji ; Ikeda, Yasuo. / Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome. In: Internal Medicine. 1996 ; Vol. 35, No. 2. pp. 105-110.
@article{22128b4ccdf5455e8ac7d20518fe3ceb,
title = "Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome",
abstract = "A portion of anticardiolipin antibodies is defined as phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and recognizes the conformationally altered β2-GPI which interacts with anionic phospholipids. We studied the clinical significance of IgG phospholipid-dependent anti-β2-GPI antibodies in patients with antiphospholipid syndrome (APS). The subjects consisted of 60 APS patients. IgG phospholipid-dependent anti-β2-GPI antibodies were detected by ELISA in 32 of the 60 patients (53{\%}). Significantly higher incidences of prolonged APTT and lupus anticoagulants were found in patients with these anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash, serositis, LE cell preparation and anti-Sm antibodies were found in patients with these anti-β2-GPI antibodies. It was found that 88{\%} of the patients with these anti-β2-GPI antibodies satisfied less than five of the revised criteria items for the classification of SLE. These findings indicate the clinical characteristics of APS patients with IgG phospholipid-dependent anti-β2-GPI antibodies.",
keywords = "Anticardiolipin antibodies, Antiphospholipid antibodies, Systemic lupus erythematosus",
author = "Junichi Kaburaki and Masataka Kuwana and Mihoko Yamamoto and Shinichi Kawai and Eiji Matsuura and Yasuo Ikeda",
year = "1996",
month = "2",
language = "English",
volume = "35",
pages = "105--110",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome

AU - Kaburaki, Junichi

AU - Kuwana, Masataka

AU - Yamamoto, Mihoko

AU - Kawai, Shinichi

AU - Matsuura, Eiji

AU - Ikeda, Yasuo

PY - 1996/2

Y1 - 1996/2

N2 - A portion of anticardiolipin antibodies is defined as phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and recognizes the conformationally altered β2-GPI which interacts with anionic phospholipids. We studied the clinical significance of IgG phospholipid-dependent anti-β2-GPI antibodies in patients with antiphospholipid syndrome (APS). The subjects consisted of 60 APS patients. IgG phospholipid-dependent anti-β2-GPI antibodies were detected by ELISA in 32 of the 60 patients (53%). Significantly higher incidences of prolonged APTT and lupus anticoagulants were found in patients with these anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash, serositis, LE cell preparation and anti-Sm antibodies were found in patients with these anti-β2-GPI antibodies. It was found that 88% of the patients with these anti-β2-GPI antibodies satisfied less than five of the revised criteria items for the classification of SLE. These findings indicate the clinical characteristics of APS patients with IgG phospholipid-dependent anti-β2-GPI antibodies.

AB - A portion of anticardiolipin antibodies is defined as phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and recognizes the conformationally altered β2-GPI which interacts with anionic phospholipids. We studied the clinical significance of IgG phospholipid-dependent anti-β2-GPI antibodies in patients with antiphospholipid syndrome (APS). The subjects consisted of 60 APS patients. IgG phospholipid-dependent anti-β2-GPI antibodies were detected by ELISA in 32 of the 60 patients (53%). Significantly higher incidences of prolonged APTT and lupus anticoagulants were found in patients with these anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash, serositis, LE cell preparation and anti-Sm antibodies were found in patients with these anti-β2-GPI antibodies. It was found that 88% of the patients with these anti-β2-GPI antibodies satisfied less than five of the revised criteria items for the classification of SLE. These findings indicate the clinical characteristics of APS patients with IgG phospholipid-dependent anti-β2-GPI antibodies.

KW - Anticardiolipin antibodies

KW - Antiphospholipid antibodies

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0030078774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030078774&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 105

EP - 110

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 2

ER -